Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

Running, not enrolling

Conditions studied: Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD), Ulcerative Colitis (UC)

In brief

The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration. Patients with IBD who are starting subcutaneous vedolizumab administration between September 1, 2023, and March 31, 2025, as part of normal patient care, will be retrospectively reviewed and analyzed.

Key facts

Study ID

NCT07123350

Run by

Vanderbilt University Medical Center

People needed

120

Starts

2025-10-16

Expected to finish

2026-12-31

Last updated by the study team

2026-05-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with Crohn's Disease or Ulcerative Colitis referred to start SC vedolizumab from a VUMC IBD provider and receive at least 1 dose of subcutaneous vedolizumab
• Age 18 years old or older

You may not qualify if…

• Patients prescribed SC vedolizumab from a non-VUMC provider
• Patients lost to follow-up or change in provider or medication before SC formulation started

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.